<SEC-DOCUMENT>0001739410-23-000004.txt : 20230808
<SEC-HEADER>0001739410-23-000004.hdr.sgml : 20230808
<ACCEPTANCE-DATETIME>20230808081608
ACCESSION NUMBER:		0001739410-23-000004
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230808
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230808
DATE AS OF CHANGE:		20230808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Rallybio Corp
		CENTRAL INDEX KEY:			0001739410
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				851083789
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40693
		FILM NUMBER:		231149458

	BUSINESS ADDRESS:	
		STREET 1:		234 CHURCH STREET
		STREET 2:		SUITE 1020
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06510
		BUSINESS PHONE:		203- 859-3820

	MAIL ADDRESS:	
		STREET 1:		234 CHURCH STREET
		STREET 2:		SUITE 1020
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06510

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Rallybio Holdings, LLC
		DATE OF NAME CHANGE:	20180502
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>rlyb-20230808.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:e9beda03-2356-4f05-98e3-b737c5372b51,g:9ab8b160-847a-4590-9f1a-76f6e407229b,d:e7af11d3cfb04c9ba4a1391ab3ae6f12--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>rlyb-20230808</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-23">0001739410</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-24">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="rlyb-20230808.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-08</xbrli:startDate><xbrli:endDate>2023-08-08</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie7af11d3cfb04c9ba4a1391ab3ae6f12_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">August 8, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">RALLYBIO CORPORATION</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Exact name of Registrant as Specified in Its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________________</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-40693</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">85-1083789</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(State or Other Jurisdiction<br/>of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">234 Church Street,</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 1020</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">New Haven,</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-10">Connecticut</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">06510</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">203</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">859-3820</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-17">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">RLYB</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-21">x</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-22">o</ix:nonNumeric></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie7af11d3cfb04c9ba4a1391ab3ae6f12_4"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02 Results of Operations and Financial Condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 8, 2023, Rallybio Corporation issued a press release announcing its financial results for the quarter ended June 30, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div id="ie7af11d3cfb04c9ba4a1391ab3ae6f12_7"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits.</span></div><div style="margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.84pt">Exhibits</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.173%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="rlyb-20230808xex991pressre.htm">Press release issued by the Company on August 8, 2023 regarding financial results for the fiscal quarter ended June 30, 2023</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie7af11d3cfb04c9ba4a1391ab3ae6f12_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RALLYBIO CORPORATION</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Jonathan I. Lieber</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jonathan I. Lieber<br/>Chief Financial Officer and Treasurer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>rlyb-20230808xex991pressre.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i738c4a244d874a6aa54a8840c7e305e1_1"></div><div style="min-height:45pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exhibit 99.1</font></div></div><div style="margin-top:12pt;text-align:center"><img alt="img96626370_0a.jpg" src="img96626370_0a.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:158px"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">-- RLYB212 Phase 1b Proof-of-Concept Study Results Presented at the 31</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> Congress of the International Society of Thrombosis and Haemostasis (ISTH) in June 2023 --</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">-- RLYB212 Phase 1 Multiple Dose Cohort Study Results Expected in 4Q 2023 --</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">-- Initial Data from RLYB116 Phase 1 Multiple Ascending Dose Study Including Safety, PK and PD Expected in 4Q 2023 --</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">-- $137.8 million cash, cash equivalents and marketable securities as of June&#160;30, 2023&#59; Provides Runway into 1Q 2025 --</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NEW HAVEN, Conn. August 8, 2023-- </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Rallybio Corporation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (Nasdaq&#58; RLYB) today reported financial results for the second quarter ended June&#160;30, 2023 and provided an update on recent program and corporate developments.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#8220;We continue to make significant progress across our portfolio. We were pleased to have results from the Phase 1b proof-of-concept study for RLYB212, our anti-HPA-1a monoclonal antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), presented at the International Society on Thrombosis and Haemostasis Congress in June. With both dose groups in the study meeting the proof-of-concept criteria of at least 90% reduction in mean platelet elimination half-life, these results continue to support the potential use of subcutaneous RLYB212 for the prevention of HPA-1a alloimmunization and FNAIT. In the fourth quarter of 2023, we plan to complete the toxicology program for RLYB212, and share the results from the multiple dose cohort of our ongoing Phase 1 study for RLYB212. In parallel, we expect to initiate regulatory discussions which will support the initiation of a Phase 2 dose confirmation study in pregnant women at higher risk of FNAIT for RLYB212 in the second half of 2024,&#8221; said Stephen Uden, M.D., Chief Executive Officer of Rallybio.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Uden continued, &#8220;We continue to advance our multiple ascending dose Phase 1 study of RLYB116, an inhibitor of complement component 5 (C5) and expect to share initial data from this study, as well as details on our initial indication strategy for RLYB116, in the fourth quarter of 2023. As we continue to fortify our position as a leader in the development of transformative medicines for underserved rare diseases, we believe our existing capital will allow us to advance our portfolio through upcoming milestones.&#8221; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Maternal Fetal Blood Disorders</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Results from the Phase 1b proof-of-concept study of RLYB212, an anti-HPA-1a monoclonal antibody in development for the prevention of FNAIT, were presented at the 31st Congress of the International Society for Thrombosis and Haemostasis in June 2023. In this study, subcutaneous RLYB212 administration produced a dose-dependent, rapid and complete elimination of transfused HPA-1a positive platelets in HPA-1a negative subjects, with both dose groups meeting the pre-specified proof-of-concept criteria of &#8805; 90% reduction in mean platelet elimination half-life. Mean platelet elimination half-life was 5.8 hours (0.09mg dose) and 1.5 hours (0.29mg dose) for RLYB212 compared to 71.7 hours for placebo. Consistent with previously reported data, RLYB212 was well-tolerated with no reports of serious or severe adverse events.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company expects to achieve the following milestones in the fourth quarter of 2023 for RLYB212&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Complete the comprehensive toxicology program for RLYB212, including maternal-fetal toxicology.  </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Report results from the multiple dose cohort of the Phase 1 safety and pharmacokinetic study of RLYB212. This multiple dose cohort, which was initiated in the first quarter of 2023, is designed to evaluate safety and pharmacokinetics of subcutaneous RLYB212 based on repeat dosing over 12 weeks.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Rallybio expects to initiate a Phase 2 dose confirmation study for RLYB212 in the second half of 2024 in order to confirm the RLYB212 dose regimen in pregnant women at higher risk of FNAIT. Following completion of the Phase 2 dose confirmation study and consultation with regulatory authorities, Rallybio expects to initiate a Phase 3 registrational study.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company also continues to advance the FNAIT natural history alloimmunization study. In June 2023, the Company announced approximately 4,500 women have been screened to date and an estimated 7,600 women are planned to be screened by the end of 2023. The Company expects screening for the natural history study to continue simultaneously with execution of the Phase 2 study. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Complement Dysregulation</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Phase 1 multiple ascending dose study of RLYB116, a novel, potentially long-acting, subcutaneously injected inhibitor of C5 in development for the treatment of patients with complement-related diseases continues to advance. This single-blind, dose escalation, placebo-controlled study is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of RLYB116 in healthy participants. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company expects to report initial data from this study in the fourth quarter of 2023 along with its initial plans for potential indications for which RLYB116 could be developed.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In July 2023, Rallybio announced the acceptance of an abstract for a poster that will report data from the Phase 1 first-in-human single ascending dose clinical study of RLYB116.  The poster will be presented at the 29th International Complement Workshop, which will take place in Newcastle, UK from August 31 to September 5, 2023. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Corporate Updates<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On August, 1, 2023, Stephen Uden, M.D. became Chief Executive Officer of Rallybio, and a member of the Board of Directors. Dr. Uden remains President of Rallybio. He succeeded Martin Mackay, Ph.D. as Chief Executive Officer.  Dr. Mackay was appointed Executive Chairman effective on August 1, 2023. As Executive Chairman, Dr. Mackay remains a full-time employee and is actively involved with the Company, with a particular focus on company strategy, investor relations and related activities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Second Quarter 2023 Financial Results&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:32.15pt">Research &#38; Development (R&#38;D) Expenses&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">R&#38;D expenses were $13.1 million for the second quarter of 2023, compared to $10.1 million for the same period in 2022.  The increase in R&#38;D expenses was primarily due to an increase in costs to advance RLYB212 and RLYB116 and an increase in R&#38;D related headcount costs, including share-based compensation expense, as compared to the prior year.</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:32.15pt">General &#38; Administrative (G&#38;A) Expenses&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">G&#38;A expenses were $7.0 million for the second quarter of 2023, compared to $7.5 million for the same period in 2022. The decrease in G&#38;A expenses was primarily due to a decrease in G&#38;A related payroll and personnel-related costs, including share-based compensation expense.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:32.15pt">Net Loss and Net Loss Per Common Share&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Net loss was $18.6 million for the second quarter of 2023, or net loss per common share of $0.46 compared to a net loss of $17.6 million, or net loss per common share of $0.57 for the second quarter of 2022.</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:32.15pt">Cash Position&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> As of June&#160;30, 2023, cash, cash equivalents and marketable securities were $137.8 million.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Rallybio</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Rallybio (NASDAQ&#58; RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The Company has two clinical stage programs&#58; RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Rallybio is headquartered in New Haven, Connecticut with an additional facility at the University of Connecticut&#8217;s Technology Incubation Program in Farmington, Connecticut. For more information, please visit </font><font style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">www.rallybio.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> and follow us on </font><font style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">LinkedIn</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> and </font><font style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Twitter</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains forward-looking statements that are based on our management&#8217;s beliefs and assumptions and on currently available information. All statements, other than statements of historical facts contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements concerning the initiation, progress, substance, design and timing of our planned or ongoing studies for RLYB212 and RLYB116, including the planned RLYB212 Phase 2 and Phase 3 studies, the timing of the availability of data from such studies, our expectations regarding reporting of data from such studies, and our expectations regarding the usefulness of data from such studies, the timing of the availability of data from the RLYB212 toxicology program and our expectations regarding the usefulness of such data, the potential markets for RLYB212 and RLYB116, the potential indications for which RLYB116 could be developed and our plans for presenting such potential indications, our estimates of our capital requirements and the sufficiency thereof, our ability to advance our portfolio, our plans for development of our inhibitor of C5 for the treatment of ophthalmic disorders, and our plans for development activities with our strategic collaboration partners. The forward-looking statements in this press release are only predictions and are based largely on management&#8217;s current expectations and projections about future events and financial trends that management believes may affect Rallybio&#8217;s business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our ability to successfully initiate and conduct our planned clinical trials, including the FNAIT natural history study, and the Phase 1 and 1b clinical trials for RLYB212 and the Phase 1 study for RLYB116, and complete such clinical trials and obtain results on our expected timelines, or at all, whether our cash resources will be sufficient to fund our operating expenses and capital expenditure requirements and whether we will be successful raising additional capital, our ability to identify new product candidates and successfully acquire such product candidates from third parties, our ability to enter into strategic partnerships or other arrangements, including such an arrangement for the development of our inhibitor of C5 for the treatment of ophthalmic disorders, competition from other biotechnology and pharmaceutical companies, and those risks and uncertainties described in Rallybio&#8217;s filings with the U.S. Securities and Exchange Commission (SEC), including Rallybio&#8217;s </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Quarterly Report on Form 10-Q for the period ended March 31, 2023, and subsequent filings with the SEC. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we are not obligated to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events, changed circumstances or otherwise.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i738c4a244d874a6aa54a8840c7e305e1_4"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financial Tables</font></div><div id="i738c4a244d874a6aa54a8840c7e305e1_7"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RALLYBIO CORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SELECTED CONDENSED CONSOLIDATED FINANCIAL INFORMATION</font></div><div id="i738c4a244d874a6aa54a8840c7e305e1_10"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FOR THE THREE MONTHS ENDED JUNE 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FOR THE SIX MONTHS ENDED JUNE 30,</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except share and per share amounts)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,130&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,138&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,332&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,786&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,953&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,477&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,125&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,147&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,083&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,615&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,457&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,933&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,083)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,615)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,457)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,933)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,608&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,154&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,670&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,289&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">580&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,413)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,245)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,168)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,353)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on investment in joint venture</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,630)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,583)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,948)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,081)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share, basic and diluted</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.46)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.57)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.89)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.05)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,363,902</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,588,931</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,306,715</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,453,913</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on marketable securities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(371)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(371)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,841)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,832)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,006)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,452)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="i738c4a244d874a6aa54a8840c7e305e1_13"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">JUNE 30,<br>2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DECEMBER 31,<br>2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and marketable securities</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,838&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,994&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,576&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,435&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,319&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,118&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,257&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,317&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="i738c4a244d874a6aa54a8840c7e305e1_16"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contacts</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Investor</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Ami Bavishi</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Head of Investor Relations and Corporate Communications</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(475) 47-RALLY (Ext. 282)</font></div><div><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">abavishi&#64;rallybio.com</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Hannah Deresiewicz</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stern Investor Relations, Inc.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">212-362-1200</font></div><div><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">hannah.deresiewicz&#64;sternir.com</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Media</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tara DiMilia</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">908-369-7168</font></div><div><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tara.dimilia&#64;tmstrat.com</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>rlyb-20230808.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:e9beda03-2356-4f05-98e3-b737c5372b51,g:9ab8b160-847a-4590-9f1a-76f6e407229b-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:rlyb="http://rallybio.com/20230808" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://rallybio.com/20230808">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rlyb-20230808_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rlyb-20230808_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://rallybio.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>rlyb-20230808_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:e9beda03-2356-4f05-98e3-b737c5372b51,g:9ab8b160-847a-4590-9f1a-76f6e407229b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_0256765c-3685-42dd-9fdc-77fc53f15558_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_ef1a60b1-6b92-4e01-835b-5f9f0fca206c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_25c5726c-b6cb-49d9-9ec5-2d2debed31b5_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_f77cb8af-2799-4966-ba17-13c8557be5c8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_495e6e99-8242-429c-beb1-fdd20c7e0014_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_6b09a00b-c9c3-4229-8643-2778702ea4e5_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_7a92528e-63e0-47f9-834f-44ac8b9af72f_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_d571d518-3bda-4446-b398-e226335c2b97_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_dd7670f9-427f-4a53-a903-836d90cecb9c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_439ccf12-bf94-4ae5-8eb2-76d67d42bd74_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3272c24b-1c4e-45f4-9078-1ab0d55c622c_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_a986c525-decc-4546-9379-7b21bcb9542c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_890e135b-65ce-410b-b8c9-2b978b5e3f88_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a368e5f6-21b2-4fea-97fd-d72488fb428c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_732f7c4d-f787-4088-8912-6d4699acc605_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_4eeb5674-652c-4030-9b58-9a72f495e6bd_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_a553fba9-7668-4cc0-9d4d-03648c0125db_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_310ea292-6664-45f0-9980-010b069404e0_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_f59cb9a2-50e3-43da-a500-aa77c3e78e1e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_51c96e8d-ca6d-4ae4-8890-17a65fd25a4f_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_22f079c0-45cd-4b14-8a44-e6daf4c88d1f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_f786580e-ac36-4959-b456-dda1d2d08054_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_6105506d-7acd-4674-bbca-a6a38eb105b4_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_ef2abe70-35d9-4799-91bd-273b8a060ef0_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>rlyb-20230808_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:e9beda03-2356-4f05-98e3-b737c5372b51,g:9ab8b160-847a-4590-9f1a-76f6e407229b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://rallybio.com/role/Cover" xlink:type="simple" xlink:href="rlyb-20230808.xsd#Cover"/>
  <link:presentationLink xlink:role="http://rallybio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b349f370-fc0b-49ba-bcae-e70aafb30f6c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_0ffa0808-24cf-4e55-aef0-9cd0edbf369b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b349f370-fc0b-49ba-bcae-e70aafb30f6c" xlink:to="loc_dei_DocumentType_0ffa0808-24cf-4e55-aef0-9cd0edbf369b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6a182fdc-2955-4cda-a78c-2a04fcc51bf2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b349f370-fc0b-49ba-bcae-e70aafb30f6c" xlink:to="loc_dei_DocumentPeriodEndDate_6a182fdc-2955-4cda-a78c-2a04fcc51bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_088c6ed0-9c84-415a-9767-677bdc9fb5d0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b349f370-fc0b-49ba-bcae-e70aafb30f6c" xlink:to="loc_dei_EntityRegistrantName_088c6ed0-9c84-415a-9767-677bdc9fb5d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_27aec59f-94ce-4780-8500-f655a17d22ed" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b349f370-fc0b-49ba-bcae-e70aafb30f6c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_27aec59f-94ce-4780-8500-f655a17d22ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_87a529c8-f533-4b08-8a4a-d170f606c993" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b349f370-fc0b-49ba-bcae-e70aafb30f6c" xlink:to="loc_dei_EntityFileNumber_87a529c8-f533-4b08-8a4a-d170f606c993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_dbc58ad4-51e5-4448-a2d1-61f2915f2897" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b349f370-fc0b-49ba-bcae-e70aafb30f6c" xlink:to="loc_dei_EntityTaxIdentificationNumber_dbc58ad4-51e5-4448-a2d1-61f2915f2897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_f3bf053f-630a-4f51-b7e8-4e3cb08767eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b349f370-fc0b-49ba-bcae-e70aafb30f6c" xlink:to="loc_dei_EntityAddressAddressLine1_f3bf053f-630a-4f51-b7e8-4e3cb08767eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_36e752a0-e7bf-4c80-acd8-cc3131c54924" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b349f370-fc0b-49ba-bcae-e70aafb30f6c" xlink:to="loc_dei_EntityAddressAddressLine2_36e752a0-e7bf-4c80-acd8-cc3131c54924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_17bb7e76-7875-472a-b8a8-8c0a0fc7da0b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b349f370-fc0b-49ba-bcae-e70aafb30f6c" xlink:to="loc_dei_EntityAddressCityOrTown_17bb7e76-7875-472a-b8a8-8c0a0fc7da0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_7d4e1328-7fc3-436f-a39d-88d05fe03961" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b349f370-fc0b-49ba-bcae-e70aafb30f6c" xlink:to="loc_dei_EntityAddressStateOrProvince_7d4e1328-7fc3-436f-a39d-88d05fe03961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_9506541f-91fb-4ecf-b119-e4e86a30a661" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b349f370-fc0b-49ba-bcae-e70aafb30f6c" xlink:to="loc_dei_EntityAddressPostalZipCode_9506541f-91fb-4ecf-b119-e4e86a30a661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_604d0bba-7653-4355-84ae-4126c0a996dc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b349f370-fc0b-49ba-bcae-e70aafb30f6c" xlink:to="loc_dei_CityAreaCode_604d0bba-7653-4355-84ae-4126c0a996dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_1dd82ee5-53e9-487b-a97e-79e9e5c56198" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b349f370-fc0b-49ba-bcae-e70aafb30f6c" xlink:to="loc_dei_LocalPhoneNumber_1dd82ee5-53e9-487b-a97e-79e9e5c56198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_8852dbcd-0342-4cc6-9f05-0dd5a117f6a8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b349f370-fc0b-49ba-bcae-e70aafb30f6c" xlink:to="loc_dei_WrittenCommunications_8852dbcd-0342-4cc6-9f05-0dd5a117f6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_5186d330-1b0b-4c84-a4b4-bf91cc5559eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b349f370-fc0b-49ba-bcae-e70aafb30f6c" xlink:to="loc_dei_SolicitingMaterial_5186d330-1b0b-4c84-a4b4-bf91cc5559eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_c97dbf1f-4af5-4ebc-8408-ee4ab388eabd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b349f370-fc0b-49ba-bcae-e70aafb30f6c" xlink:to="loc_dei_PreCommencementTenderOffer_c97dbf1f-4af5-4ebc-8408-ee4ab388eabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_8c647e20-9c28-46c8-a8d2-c0141c3d1886" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b349f370-fc0b-49ba-bcae-e70aafb30f6c" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_8c647e20-9c28-46c8-a8d2-c0141c3d1886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_05a3ccfa-b7c6-48b2-aaa7-a5c691cb39fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b349f370-fc0b-49ba-bcae-e70aafb30f6c" xlink:to="loc_dei_Security12bTitle_05a3ccfa-b7c6-48b2-aaa7-a5c691cb39fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3c1d3f5d-d84e-441c-882e-2daf03d53a9f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b349f370-fc0b-49ba-bcae-e70aafb30f6c" xlink:to="loc_dei_TradingSymbol_3c1d3f5d-d84e-441c-882e-2daf03d53a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_fe65a87a-47cd-4d79-8825-34c9a1e9cdf6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b349f370-fc0b-49ba-bcae-e70aafb30f6c" xlink:to="loc_dei_SecurityExchangeName_fe65a87a-47cd-4d79-8825-34c9a1e9cdf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_f58ced58-6799-4b6c-bf68-af37af630729" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b349f370-fc0b-49ba-bcae-e70aafb30f6c" xlink:to="loc_dei_EntityEmergingGrowthCompany_f58ced58-6799-4b6c-bf68-af37af630729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_2a11aabb-a72f-436d-8c24-190b726ee549" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b349f370-fc0b-49ba-bcae-e70aafb30f6c" xlink:to="loc_dei_EntityCentralIndexKey_2a11aabb-a72f-436d-8c24-190b726ee549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_44908bc5-86c9-4d10-bd41-59fba44de1cd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b349f370-fc0b-49ba-bcae-e70aafb30f6c" xlink:to="loc_dei_AmendmentFlag_44908bc5-86c9-4d10-bd41-59fba44de1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_37f51810-bdff-4e2d-b218-7da06c8d5557" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b349f370-fc0b-49ba-bcae-e70aafb30f6c" xlink:to="loc_dei_EntityExTransitionPeriod_37f51810-bdff-4e2d-b218-7da06c8d5557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img96626370_0a.jpg
<TEXT>
begin 644 img96626370_0a.jpg
M_]C_X  02D9)1@ ! 0        #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  M )L# 2(  A$! Q$!_\0
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MV,]0&V#N/< QQRZL?S![9,3<<;?P[EP/@<#C<//"*-'ZKOB!-1#52]UK!O\
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M;7#Y"2K&O]$CJKJH?MF:4>@]GIRV@2$D[28H"*+0B[M914K=(?32ZQ*7Z<
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MA@ R503!@=]AP.! =\Y$1#8!\<5!,](9SG(YR.1[CYP&WL& P&WCA9B+UO\
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M8#(?J30'CO\ \M6&0$<><=O_ )P3"GU #DF1!Q$F T M,F$X=( %JTBX$P[
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M(/H<F*/=SI_\8'*-$0+@-4 %# #C!:LH<I2@ !C8H 'N ^.P#C*AZTJGG/\
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MUEVD4LZ,J*PK'AFTNE&!]8@(I$;D;B( 44>C)1),),;@.-PVP.,B/MG& ]A
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139684809354528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 08, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  08,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">RALLYBIO CORPORATION<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-1083789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">234 Church Street,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Haven,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">06510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">859-3820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RLYB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001739410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>rlyb-20230808_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rlyb-20230808.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
        </entity>
        <period>
            <startDate>2023-08-08</startDate>
            <endDate>2023-08-08</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-23">0001739410</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-24">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2023-08-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">RALLYBIO CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-40693</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">85-1083789</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">234 Church Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 1020</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">New Haven,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">CT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">06510</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">203</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">859-3820</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">RLYB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-22">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    (  -""%<'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  #0@A77M\XK^X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L,P#(9?9?B>R$D@#)/ZLK%3"X,5-G8SMMJ:Q8FQ-9*^_1RO31G; PQ\L?3[
MTR=PI[W08\#G,'H,9#'>S:X?HM!^PTY$7@!$?4*G8ID20VH>QN 4I6LX@E?Z
M0QT1:LY;<$C**%*P  N_$IGLC!8ZH*(Q7/!&KWC_&?H,,QJP1X<#1:C*"IA<
M)OKSW'=P RPPPN#B=P'-2LS5/[&Y ^R2G*-=4],TE5.3<VF'"MYVVY>\;F&'
M2&K0F%Y%*^CL<<.NDU^;A\?]$Y,UKYN"WZ>SKVI1M8*W[XOK#[^;L!N-/=A_
M;'P5E!W\^A?R"U!+ P04    "  #0@A7F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M  -""%>(0B?>>P0  +@1   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MG9AK<^(V%(;_BL;M=-J9)-CF$DB!&4+(+K/90(%VI^WT@[ %UL267$GF\N][
M9(A-N^9 ]PNV;)^71SI'KV1WMU*]Z8@Q0W9)+'3/B8Q)'VHU'40LH?I.IDS
MG954"3705.N:3A6C81Z4Q#7?=5NUA'+A]+OYM:GJ=V5F8B[85!&=)0E5^T<6
MRVW/\9SW"S.^CHR]4.MW4[IF<V9^3:<*6K5")>0)$YI+011;]9R!]_#HMVQ
M_L1OG&WUR3FQ75E*^68;X[#GN):(Q2PP5H+"8<.&+(ZM$G#\?11UBO^T@:?G
M[^K/>>>A,TNJV5#&7WAHHI[3=DC(5C2+S4QN/[)CAYI6+Y"QSG_)]O!LH^&0
M(--&)L=@($BX.!SI[C@0IP'^F0#_&.#GW(<_RBF?J*']KI);HNS3H&9/\J[F
MT0#'A<W*W"BXRR'.](=RPU2W9D#*7J@%Q[#'0YA_)FR0K>^(V[XAONO7_QU>
M X("PR\P_%ROCF&0/P=+;10DZJ\JHH-"HUK!5N^#3FG >@Z4IV9JPYS^#]]Y
M+?=GA*]>\-4Q]?Z3##*H14,6^Y15P>'A[=M/"$2C@&A<!S%EBLN0C$1((.F5
M/+A2GKX\?Y<2V"S8FJCB2!AN]F3&UMRF$"!?:5))ANO,!B\OOS^.)V0XF4TG
ML\%B/'E%\%H%7NL:O+$(I$JEHM81;LC<P.@1J<A09L*H/1S#2F9<_&F$$-X7
MA/?7$#[SF)'7+%E6STI<PW6]VX;;ZF );1<\[6MX%G1'QB$4'5_Q(!\VA Y7
M;#=O/;==OV]W$+Q.@=>Y!F\0AC#9]<W["7F!Y\A$5&815_3K#3*,,A5$4!<*
M_/0&P?3<TE_=;P==;&6E]^*2\XQ#V7JN[V*$)RN ][\(A[8%DV(AMZ*2#I=[
MA97X(]TP@8Y?N3!XJ*]_15?,V:F2&RZ"RDQ?T!PN,+1R3?!P5_\OVE1J0V/R
M!T_/&LD%1;?5]-"DEDN%ASM\GL0![-/.H^ "OHNYB%>N"QYNZ"\R@#&91E)@
MOG9!I-WLW-;;>+V72X&'V_47Q8UA @8F23)Q=#5=284+K6BL&894>K^'&_=<
MQCS@AHLU^0SEK3B-*WEPE8L\I?=[N%5/%;L-8'@8S*_#MH>)$#9HD]7J3/YP
MO8MDI>U[N$M_13;6.@.RBX"X["5 O_1['S?G!3>P@LL5\?P?ES^1.0LRJ+=]
MY8865[+U"<OMW,C@[8:D5)$-C3-&OG?O7%CI20K]U1%5*'>Y"OBX;2\4#6W]
MS??)4E96WP6!&>S;,)*35P'<G=^'C(QV043%FIW=2EX0>AW,GP:_8$REU?M7
M6?TH86IM1^D#*)C(6DA*175R<4&C,C1OI='[N$\?R88P%Q08[1BFP8Y\8M5,
MN)2MJOMZIX$N07[I_#YNV@.8GV$^1Y]CNJ[DP04N3LK2\OVKMO^C'8$R%YKG
M^]C#6U0EUS?Z?NWD/=Q^T_A,;;5H$K,5"+EW]]!?=?A,<&@8F>:OYDMIX$4_
M/XT8!2.S#\#]E93FO6'?]HN/-?U_ %!+ P04    "  #0@A7GZ ;\+$"  #B
M#   #0   'AL+W-T>6QE<RYX;6S=5VUKVS 0_BM"/V!N8FKBD1BV0&&PC4+S
M85^56'8$>O%DN7/ZZZ>S;"=I=67=A['-H<G=/;J[1W<GF:Y;=Y+\X<BY([V2
MNMW0HW/-^R1I#T>N6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[
M=:=<2PZFTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2Q
MQ'DJ?$,78&F? KP(&K <XRBAC05C$C*$[_VX_!DP::U7A90SP24-AF+=,.>X
MU7=>&18/QA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_P
MZTR3 .B<45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GTA$8Q
MA D*Q+^,%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R
M]$&*6BL>]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.
MRW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7>>9 ]IV0
M3NA1.XJRY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_
MAOMHD<VWL,\E=,E[7FY'U=;[021>\%G'!QR>(W?#$T<PGX#%$<"P/!@#S"=X
M87G^I_VLT/T$#..VBB(KU&>%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%
MZI9E\!>/AG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[
MC>4!#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS
M/(X %F>0IA@"IQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04    "  #
M0@A7EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0
M(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I
M6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE
M/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6
MFD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#
M!!0    (  -""%>JQ"(6,P$  "("   /    >&PO=V]R:V)O;VLN>&ULC5'1
M;L(P#/R5*A^P%K0A#5%>0-N0I@V-B??0NM0BB2O'A8VOG]NJ&M)>]I3<V;K<
M7187XM.!Z)1\>1=B;FJ19IZFL:C!VWA'#02=5,3>BD(^IK%AL&6L <2[=)IE
ML]1;#&:Y&+6VG-X"$B@$*2C9$7N$2_R==S Y8\0#.I3OW/1W!R;Q&-#C%<K<
M9":)-5U>B/%*0:S;%4S.Y68R#/; @L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1RE
MW^CUK7H\@RX/J!5Z0B? :ROPS-0V&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B
M]1!DZ)'!=09#K+&))@G60VY6= ;N\N@#FW+()FKJIBF>HPYX4P[V1D\E5!B@
M?%.9J+SV4VPYZ8Y>9WK_,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04    "  #
M0@A7)!Z;HJT   #X 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
MM9$]#H,P#(6O$N4 -5"I0P5,75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)
M3I]H%'=NH+;S)$9K!LIDR^SO *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8
M,V2>[IFBG#S^0W1UW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):B
MJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%
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M?^:+X3]>?P%02P$"% ,4    "  #0@A7!T%-8H$   "Q    $
M    @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (  -""%=>WSBO
M[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    (  -""%>97)PC$ 8  )PG   3              "  <P!  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @  T((5XA")]Y[!   N!$
M !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+
M 0(4 Q0    (  -""%>?H!OPL0(  .(,   -              "  ;X,  !X
M;"]S='EL97,N>&UL4$L! A0#%     @  T((5Y>*NQS     $P(   L
M         ( !F@\  %]R96QS+RYR96QS4$L! A0#%     @  T((5ZK$(A8S
M 0  (@(   \              ( !@Q   'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    (  -""%<D'INBK0   /@!   :              "  >,1  !X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (  -""%=ED'F2&0$
M ,\#   3              "  <@2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@     )  D /@(  !(4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="rlyb-20230808.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="rlyb-20230808.htm">rlyb-20230808.htm</File>
    <File>rlyb-20230808.xsd</File>
    <File>rlyb-20230808_lab.xml</File>
    <File>rlyb-20230808_pre.xml</File>
    <File>rlyb-20230808xex991pressre.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "rlyb-20230808.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 24
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "rlyb-20230808.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rlyb-20230808_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rlyb-20230808_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "rlyb-20230808.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "rlyb",
   "nsuri": "http://rallybio.com/20230808",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20230808.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://rallybio.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rlyb-20230808.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001739410-23-000004-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001739410-23-000004-xbrl.zip
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M#4-0NZXLO@&43/6QR)&$>AP5[-^IO+I+,GW_6QHR8NG9BAHY!ND;3LILYE<
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MGCJ?6N*H\04U0.]%NSWBCB>#(72<6/D>3'@)O"WD7FK><S::=-O"V-5IJ\W
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MW\0'^^K-B^T[Z?J_RGCSXG]02P,$%     @  T((5P!^-I$)!P  !S4  !4
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M(NG.L'BS>*+C.1PXVGLXT;UT_YLYVOL?4$L#!!0    (  -""%?7DH#2WQP
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M%J[V0EB;N>R&?A@=_F33?T=XI=+C ^F/#_]^'$GN_]U2/% 5)2+9TY>5_$O
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M%^W:;/8"\QF[EKU8A-J9+$XMRUZ .Q:!?O_EIWKGB)WF_+O]K_3;Z2OJQ K
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M%FZ=4+;RC95>OLY@P1WP""%/)VT&R,:A+UV<5S?-35=R<'7Q*,RG!9$.ID%
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MF]@_C8?-S.9RE2[-B(*^UG:J!_7EE^VJL_3:JF&=6M7N+']TU;"KKS7LUM,
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M*1Z,QS^&A:\?6+7FIL<[EQ;^F9S\ U#)6R3.P\H+K37*"\]=3(BYNZ!>\)Q
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M>."__2]02P$"% ,4    "  #0@A71G/]O.\.   L:@  $0
M@ $     <FQY8BTR,#(S,#@P."YH=&U02P$"% ,4    "  #0@A7+&:E:&L"
M  !D!P  $0              @ $>#P  <FQY8BTR,#(S,#@P."YX<V102P$"
M% ,4    "  #0@A7FFCU"OH*  #Z9   %0              @ &X$0  <FQY
M8BTR,#(S,#@P.%]L86(N>&UL4$L! A0#%     @  T((5P!^-I$)!P  !S4
M !4              ( !Y1P  ')L>6(M,C R,S X,#A?<')E+GAM;%!+ 0(4
M Q0    (  -""%?7DH#2WQP  #T1 0 >              "  2$D  !R;'EB
M+3(P,C,P.# X>&5X.3DQ<')E<W-R92YH=&U02P4&      4 !0!0 0  /$$
#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
